RPRX

Royalty Pharma plc
D

RPRX

54.810
USD
-0.63
(-1.14%)
مفتوح الان
حجم التداول
56,072
الربح لكل سهم
1
العائد الربحي
1.7
P/E
29
حجم السوق
24,295,853,640
أصول ذات صلة المقالات
المزيد

العنوان: Royalty Pharma plc

القطاع: Healthcare
الصناعة: Biotechnology
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.